Amgen (AMGN)

As of 15 October 2026, short interest in AMGN is 13,378,638 shares, down 684,879 shares over the last month. Over the last 48 readings it ranged from 8,822,777 shares (31 October 2024) to 16,158,990 shares (28 February 2025). At the reported average volume of 2.7M shares a day that is 5.0 days to cover.

<iframe src="https://xoomar.com/embed/stocks/amgn" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 28 October 2026, the short share of AMGN volume is 70.2%, up 4.8 points over the last five sessions. Over the last 30 readings it ranged from 34.9% (2 October 2026) to 71.8% (29 September 2026). The latest reading sits at the top of that range. The latest reading is 15.5 points above the 30-session average of 54.8%, on 671K shares reported.

As of 30 September 2026, the fails-to-deliver balance in AMGN is 9,255 shares, up 7,307 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (22 September 2026) to 19,185 shares (21 August 2026).

Insiders at AMGN reported 6 open-market sells worth $4.1M in the last 90 days and no open-market buys. Latest filing: Khosla Rachna (SVP, Business Development) on 2026-08-13.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

10 Form 144 notices on file for AMGN worth $29.0M at the prices reported; 4 in the last 90 days worth $3.7M. Latest: Khosla Rachna filed on 2026-08-13 to sell 1,252 shares ($517K) from 2026-08-13.

2 holders report 5% or more of AMGN in their latest filing, all on Schedule 13G (passive). The largest reported stake is Vanguard Capital Management at 7.5% of the class (40,510,484 shares), filed 2026-04-29 for an event on 2026-03-31.

7 of the 30 tracked managers held AMGN at their latest 13F, $1.85B in total at quarter-end prices. Fisher Asset Management is the largest at $575.6M (0.2% of its portfolio) as of 2026-06-30. Over the prior quarter 6 added shares and 1 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q2 FY 2026 (quarter ended 2026-06-30) Amgen reported revenue of $10.05B, up 9.5% from the same quarter a year earlier, and net income of $2.38B (4.37 diluted EPS). In FY 2025 it generated $9.96B of operating cash flow and spent $5.12B on dividends. As of 2026-06-30, cash was $13.99B against $57.30B of debt.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-30 from the cover page.

1 contract action on file for AMGN: $66.0M obligated in the last 90 days and $66.0M in the last 12 months across 1 awarding agency. The largest was $66.0M from the Department of Health and Human Services on 2026-08-04 (eo14398 for far 52.222-90, updated hhsar and exercise option period 4a for $65,698,998.00). This covers the largest contract actions, not every award, and agencies report late.